Publication:
Effects of Sustained-Release Beraprost in Patients With Primary Glomerular Disease or Nephrosclerosis: CASSIOPEIR Study Results

Issued Date

2020-02-01

Resource Type

Article

ISSN

17449987
17449979

DOI

10.1111/1744-9987.12840

Other identifier(s)

2-s2.0-85077222684

Rights

Mahidol University

Rights Holder(s)

SCOPUS

Bibliographic Citation

Therapeutic Apheresis and Dialysis. Vol.24, No.1 (2020), 42-55

Suggested Citation

Hidetomo Nakamoto, Xue Qing Yu, Suhnggwon Kim, Hideki Origasa, Hongguang Zheng, Jianghua Chen, Kwon Wook Joo, Suchai Sritippayawan, Qinkai Chen, Hung Chun Chen, Yoshiharu Tsubakihara, Hirofumi Tamai, Sang Heon Song, Indralingam Vaithilingam, Kang Wook Lee, Kuo Hsiung Shu, Stanley Hok-King Lo, Masanao Isono, Hajimu Kurumatani, Kiyonobu Okada, Hiroyuki Kanoh, Takashi Kiriyama, Shunsuke Yamada, Toshiro Fujita Effects of Sustained-Release Beraprost in Patients With Primary Glomerular Disease or Nephrosclerosis: CASSIOPEIR Study Results. Therapeutic Apheresis and Dialysis. Vol.24, No.1 (2020), 42-55. doi:10.1111/1744-9987.12840 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/49636

Research Projects

Organizational Units

Authors

Journal Issue

Thesis

Title

Effects of Sustained-Release Beraprost in Patients With Primary Glomerular Disease or Nephrosclerosis: CASSIOPEIR Study Results

Author(s)

Hidetomo Nakamoto
 Xue Qing Yu
 Suhnggwon Kim
 Hideki Origasa
 Hongguang Zheng
 Jianghua Chen
 Kwon Wook Joo
 Suchai Sritippayawan
 Qinkai Chen
 Hung Chun Chen
 Yoshiharu Tsubakihara
 Hirofumi Tamai
 Sang Heon Song
 Indralingam Vaithilingam
 Kang Wook Lee
 Kuo Hsiung Shu
 Stanley Hok-King Lo
 Masanao Isono
 Hajimu Kurumatani
 Kiyonobu Okada
 Hiroyuki Kanoh
 Takashi Kiriyama
 Shunsuke Yamada
 Toshiro Fujita

Other Contributor(s)

Anjo Kosei Hospital
 Shenyang General Hospital of PLA
 Kaohsiung Medical University Chung-Ho Memorial Hospital
 University of Tokyo
 Chungnam National University
 University of Toyama
 Seoul National University Hospital
 Saitama Medical University
 Toray Industries, Inc.
 Astellas Pharma Inc., Japan
 Faculty of Medicine, Siriraj Hospital, Mahidol University
 Nanchang University
 Veterans General Hospital-Taichung Taiwan
 Pusan National University, College of Medicine
 Zhejiang University
 Pamela Youde Nethersole Eastern Hospital
 Jikei Institute
 Hospital Taiping
 Sun Yat-sen University

Abstract

© 2019 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy TRK-100STP, a sustained-release preparation of the orally active prostacyclin analogue beraprost sodium, targets renal hypoxia. This study aimed to show the superiority of TRK-100STP over placebos in patients with chronic kidney disease (with either primary glomerular disease or nephrosclerosis) to determine the recommended dose. CASSIOPEIR (Chronic Renal Failure Asian Study with Oral PGI2 Derivative for Evaluating Improvement of Renal Function) was a randomized, double-blind, placebo-controlled study conducted at 160 sites in seven Asia-Pacific countries and regions. Eligible patients (n = 892) were randomized to TRK-100STP 120, 240 μg, or placebo for a treatment period of up to 4 years. The primary efficacy endpoint was time to first occurrence of a renal composite: doubling of serum creatinine or occurrence of end-stage renal disease. No significant differences were observed in composite endpoints between TRK-100STP and placebo (P = 0.5674). Hazard ratios (95% CI) in the TRK-100STP 120 and 240 μg vs. placebo groups were 0.98 (0.78, 1.22) and 0.91 (0.72, 1.14), respectively. The overall incidence of adverse events and adverse drug reactions was comparable between treatment arms.

Keyword(s)

Medicine

Availability

URI

https://repository.li.mahidol.ac.th/handle/20.500.14594/49636

Collections

Scopus 2020